Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pds.5646 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies.
Front Pharmacol
August 2025
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Background: While progress has been made in oncology treatments, including the introduction of combination therapies, barriers affect patient access. There are approaches that could improve access including combination-specific pricing that allow the price to reflect whether a product is used in monotherapy or in combination. The feasibility of this solution requires data on the utilization of combination therapies.
View Article and Find Full Text PDFRisk of Opioid Overdose Associated with Concurrent Use of Hydrocodone and CYP3A4-inhibiting Calcium Channel Blockers: A Population-based Cohort Study.
Am J Epidemiol
September 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Non-dihydropyridine calcium channel blockers (CCBs), including diltiazem and verapamil, inhibit cytochrome P450 3A4 (CYP3A4), an enzyme involved in the metabolism of hydrocodone, the most commonly used opioid in the United States (US). This study evaluated whether concomitant use of hydrocodone with CYP3A4-inhibiting CCBs increases the risk of opioid overdose compared to use of hydrocodone with amlodipine, a CCB that does not inhibit CYP3A4. Using three US databases (2000-2021), two cohorts were identified: (1) hydrocodone initiation while on CCB; and (2) CCB initiation while on hydrocodone.
View Article and Find Full Text PDFIncreased use of psychiatric drugs in Brazil over the years: evidence from a country-wide dataset.
Trends Psychiatry Psychother
September 2025
Programa de Pós-Graduação em Ciências Biológicas - Bioquímica, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Objectives: Stressful events can impact the incidence of psychiatric disorders and, therefore, psychiatric drug use. However, it is not clear whether psychiatric drug use is stable or not across the Brazilian population over time. The aim of this study was to investigate trends in psychiatric drug sales in Brazil over the years, using sales data from private-sector pharmacies as a proxy for psychiatric drug consumption.
View Article and Find Full Text PDFBig Data in the Assessment of Medication Safety in Pregnancy: Opportunities and Challenges.
Paediatr Drugs
September 2025
Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.
Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.
JAMA Dermatol
September 2025
Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)-UMR_S 1085, Rennes, France.
Importance: The cardiovascular impact of biologics used in psoriasis is not fully understood. Several studies have suggested that the inhibition of the T-helper 17 cell pathway could lead to the destabilization of atherosclerotic plaques, leading to major adverse cardiovascular events (MACEs).
Objective: To assess whether the initiation of interleukin (IL)-17(R)A inhibitors triggers MACEs.